Research programme: COVID-19 infections - Berono group/Tianjin University
Alternative Names: single domain antibody - Beroni GroupLatest Information Update: 01 Nov 2021
At a glance
- Originator Beroni Group; Tianjin University
- Class Antibodies; Antivirals
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical COVID 2019 infections
Most Recent Events
Development Overview
Introduction
A coronavirus therapeutic is being jointly developed by Berono group and Tianjin University for the treatment of COVID-2019 infections caused by SARS-CoV-2 using nanobody-based technology. The therapeutic will be developed by leveraging computer-aided drug design to predict the complex structure of SARS-CoV-2 with various neutralizing antibodies. The nano body based technology will also be used to identify the crystal structure of nano-antibodies and antigens, as well as understand the structural binding between antigens. The development of binding nanobodies improves the detection rate as well as the accuracy of SARS-CoV-2 and also facilitates the treatment of COVID-19. Preclinical development is underway in China.
Company Agreements
In February 2020, Beroni Group entered into a research and development agreement with Tianjin University in China to develop targeted treatment and quick detection technique for COVID-2019-infections. [1]
Key Development Milestones
In October 2021, Beroni group announced that the data demonstrating structure of single domain antibodies for COVDO-2019 infections. The team has identified four sdAbs targeting different regions of nucleocapsid protein with high affinities that have future potential to be used in viral detection and therapeutic purposes [2]
In March 2020, Beroni group announced that the research of medical solution has advanced into the cytological experiments. Beroni plans to conduct animal experiments followed by clinical trials in April 2020 [3] .
Drug Properties & Chemical Synopsis
- Route of administration Parenteral
- Formulation unspecified
- Class Antibodies, Antivirals
- Mechanism of Action Immunomodulators
-
WHO ATC code
J05 (Antivirals for Systemic Use)
-
EPhMRA code
J5 (Antivirals for Systemic Use)
Development Status
Summary Table
| Indication | Qualifier | Patient Segment | Phase | Countries | Route / Formulation | Developers | Event Date |
|---|---|---|---|---|---|---|---|
| COVID 2019 infections | - | - | Preclinical | China | Parenteral / unspecified | Beroni Group, Tianjin University | 28 Oct 2021 |
Commercial Information
Involved Organisations
| Organisation | Involvement | Countries |
|---|---|---|
| Tianjin University | Originator | China |
| Beroni Group | Originator | Australia |
| Beroni Group | Owner | Australia |
| Tianjin University | Owner | China |
Future Events
| Expected Date | Event Type | Description | Updated |
|---|---|---|---|
| 30 Apr 2020 | Trial Update | Beroni plans to conduct animal experiments followed by clinical trials in April 2020 [3] | 13 Mar 2020 |
Development History
| Event Date | Update Type | Comment |
|---|---|---|
| 28 Oct 2021 | Trial Update | Beroni Group plans a clinical trials in COVID-2019 infections [2] Updated 01 Nov 2021 |
| 09 Mar 2020 | Trial Update | Beroni plans to conduct animal experiments followed by clinical trials in April 2020 [3] Updated 13 Mar 2020 |
| 20 Feb 2020 | Licensing Status | Beroni group collaborates with Tianjin University to develop coronavirus therapeutic [1] Updated 28 Feb 2020 |
| 20 Feb 2020 | Phase Change | Early research in COVID-2019-infections in China (Parenteral) before February 2020 [1] Updated 28 Feb 2020 |
References
-
Beroni Group Collaborates with Tianjin University to Develop Novel Solution for Coronavirus (COVID-19).
Media Release -
Beroni Group Published an Article Related to Single-Domain Antibodies in the FEBS Journal.
Media Release -
Beroni Group Advances Research and Development of Medical Solution for Coronavirus (COVID-19).
Media Release
Adis International Ltd. Part of Springer Science+Business Media
© Springer Nature Switzerland AG